Treatment Evolutions in Prostate Cancer: DNA Damage Response and the Therapeutic Rationale for PARP Inhibition

Treatment Evolutions in Prostate Cancer:

DNA Damage Response and the Therapeutic Rationale for PARP Inhibition

Your Information

Before proceeding, please enter your information. To receive your certificate, your email and full name must be provided.

First Name

Last Name

Qualifier

Do you give consent to CUA sharing only your name and location to program sponsors?

Yes

This program has received financial support from:

SPONSORS: AstraZeneca & Merck

The CUA is committed to providing high-quality CPD programs that are fair and balanced. If you have perceived any bias in this presentation or have any feedback, please contact:

Tal Erdman
Coordinator, CPD Programs and Accreditation, Office of Education

tal.erdman@cua.org